Anbio Biotechnology (NNNN) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2025 was $4.58 million, down from $5.85 million year-over-year.

• Net income increased to $3.80 million from $3.60 million for the same period in 2024.

• Approximately 94.6% of commercial IVD revenue was from non-COVID products, reflecting a strategic shift.

Financial highlights

• Gross profit rose to $4.2 million with a gross margin of 92.3%, up from $3.9 million and 66.9% in 2024.

• Operating income was $3.4 million, slightly down from $3.6 million year-over-year.

• Basic and diluted EPS were $0.087, compared to $0.085 in the prior year.

Outlook and guidance

• Current cash, IPO proceeds, and operational cash flow are expected to cover operating and capital needs for at least the next twelve months.